So therapeutic strategies based on the adoptive transfer of IL-12 and IL-18 in combination preactivated NK cells might have an important place in immunotherapy of metastatic melanoma patients with better survival outcome and prognosis. This evidence concerns the gene IL18 and metastatic melanoma.